Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Ups Penalties For Quality Violators Under Tougher Regulation

This article was originally published in PharmAsia News

Executive Summary

The China FDA has officially released a new regulation governing unannounced inspections for drug and device manufacturers, ranging from production to distribution to product use, with many expecting more frequent inspections and stricter enforcement. Although traditional medicine manufacturers are the main target for now, the scope of focus could be expanded.

You may also be interested in...



CanSino Moving Coronavirus Vaccine To Phase III

CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.

Doubts Over China's First Alzheimer's Drug Resurface Amid Research Miscount Allegation

Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.

Boehringer Bets On External Innovation In Post-COVID China

From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel